Wegovy is one of two brand names for semaglutide approved specifically for weight management (the other being Ozempic, approved for type 2 diabetes). It represents a standardised commercial product with a fixed dose escalation protocol. Compounded semaglutide uses the same active pharmaceutical ingredient but is prepared in a licensed compounding facility under physician prescription, without the brand-name packaging or pricing.
Understanding what is genuinely different - and what is not - helps you make a better-informed decision about your treatment pathway.
What Is Wegovy?
Wegovy is semaglutide at a target maintenance dose of 2.4 mg weekly, following a standardised 16-week dose escalation protocol starting at 0.25 mg. It comes in a pre-filled autoinjector pen and is manufactured by Novo Nordisk.
In the STEP trials, Wegovy produced average weight loss of 14.9 percent of body weight over 68 weeks, making it the most effective FDA-approved weight loss medication at the time of its launch.
What Is Compounded Semaglutide?
Compounded semaglutide is prepared by a licensed compounding pharmacy using pharmaceutical-grade semaglutide API (active pharmaceutical ingredient). It is prescribed by a physician to a specific patient at a specific dose, based on that patient's clinical profile.
The active molecule is identical to the semaglutide in Wegovy. The differences lie in the preparation format, dosing flexibility, and the absence of brand-name pricing.
Key Differences: What Actually Matters
Dosing Flexibility
Wegovy uses a fixed escalation schedule: 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg maintenance, with four weeks at each step. For many patients, this fixed schedule escalates faster than optimal, leading to more side effects.
Compounded semaglutide can be prepared at any intermediate dose and held at any step for as long as the patient needs to adapt. This flexibility is clinically meaningful for managing side effects and improving tolerability.
Availability and Cost in India
Wegovy is not widely available in India and where available, carries a substantial import-related cost. Physician-supervised compounded semaglutide is the practical access route for most Indian patients.
Clinical Oversight
Wegovy as a brand product does not inherently include biomarker testing, physician monitoring, or protocol adjustment. A compounded semaglutide program through Longegra explicitly includes all of these as core components.
Regulatory Status
Wegovy is an approved pharmaceutical product in the United States and several other markets. In India, semaglutide compounding under physician prescription is the standard clinical pathway and operates within the regulatory framework governing pharmaceutical compounding.
What Is the Same
- Active molecule: Identical semaglutide API
- Mechanism of action: GLP-1 receptor agonism, identical pathway
- Clinical outcomes (when properly compounded and dosed): Equivalent weight loss and metabolic improvement
- Side effect profile: Essentially identical, modulated by titration speed
When Is Wegovy the Better Choice?
For patients in markets where Wegovy is commercially available at accessible pricing, the brand product offers manufacturing standardisation that compounding cannot fully replicate, and the regulatory approval process provides a form of quality assurance. If you are in a market where Wegovy is genuinely accessible and affordable, it is a legitimate and well-validated option.
When Is Supervised Compounding the Better Choice?
For the large majority of Indian patients, physician-supervised compounded semaglutide is the more accessible, more flexible, and more comprehensively supported option. It delivers:
- The same active molecule at a fraction of brand-name cost
- More granular dose titration for better tolerability
- Integrated biomarker testing and physician oversight that brand retail does not include
- A personalised program structure rather than a fixed commercial protocol
Frequently Asked Questions (FAQs)
The active molecule is the same. The formulation vehicle, stabilisers, and delivery format may differ between a compounded preparation and the Wegovy autoinjector. Pharmaceutical-grade compounding from a regulated facility produces a clinically equivalent product.
